Finding 401776 (2023-005)

Significant Deficiency Repeat Finding
Requirement
H
Questioned Costs
$1
Year
2023
Accepted
2024-06-24
Audit: 309693
Auditor: Bdo

AI Summary

  • Core Issue: Expenses totaling $87 were incurred outside the award's period of performance, leading to noncompliance.
  • Impacted Requirements: Compliance with §200.309 and §200.344(b) regarding allowable costs and liquidation of obligations.
  • Recommended Follow-Up: Revise internal procedures to better detect out-of-period expenses and consider closing projects in the accounting system to manage costs incurred after the award period.

Finding Text

Internal Controls over Compliance and Compliance with the Period of Performance Compliance Requirement See Schedule of Findings and Questioned Costs for chart/table. Criteria or Specific Requirement: In accordance with §200.309, a non-Federal entity may charge to the Federal award only allowable costs incurred during the period of performance and any costs incurred before the Federal awarding agency or pass-through entity made the Federal award that were authorized by the Federal awarding agency or pass-through entity. Unless the Federal awarding agency or pass-through entity authorizes an extension, a non-Federal entity must liquidate all obligations incurred under the Federal award not later than 120 calendar days after the end date of the period of performance as specified in the terms and conditions of the Federal award as required by §200.344(b). When used in connection with a non-Federal entity’s utilization of funds under a Federal award, “obligations” means orders placed for property, services, contracts, and subawards made, and similar transactions during a given period that require payment by the non-Federal entity during the same or a future period as described in §200.71. Condition: We identified three instances out of 25 sample items selected, whereby expenses were incurred outside of the award period of performance. These expenses totaled $85 for award 72052020CA00002 and $2 for award AID-OAA-A-11-00012. Questioned Costs: For Award 72052020CA00002, we identified $85 in known questioned costs as a result of our sampling and testing procedures related to the close-out period of the award. Context: BDO’s testing of the period of performance compliance requirement was performed by examining whether the expenses selected as part of our testing of allowable costs and allowable activities were incurred within the proper period of performance of the award. Testing of 120 expenses for AL# 98.001 resulted in no exceptions to the period of performance requirements. BDO also performed specific period of performance procedures on those awards that began or ended during 2023. A total of 25 expenses for AL# 98.001 were selected across the awards that began or ended during 2023, and the two compliance matters identified above resulted from those specific 25 items tested for AL# 98.001. Cause: PSI management has procedures in place to review expenditures to determine the appropriate period of performance; however, those procedures were not performed to a level of detail to identify expenses that were incurred outside the period of the award. Effect: The lack of adherence to the established internal control procedures around the period of performance of the award resulted in noncompliance and questioned costs that need to be returned to the U.S. Agency for International Development. Continued noncompliance with federal statutes, regulations, and the provisions of the award agreements could ultimately result in additional disallowed costs for the major program. Repeat Finding: This finding is a repeat finding and was reported as finding 2022-006 in the 2022 schedule of findings and questioned costs. Recommendation: We recommend management revisit and consider revising their internal procedures around detecting expenditures incurred outside of the period of performance in order to prevent the charging of costs outside of the period of performance of the award. Furthermore, we believe an option would be to close the project within the accounting system, and create a separate project to accumulate any costs incurred after the end of the period of performance. The costs incurred subsequent to the end of the period of performance should go through the review and approval of individuals at PSI Headquarters. Views of Responsible Officials: PSI management agrees with the finding and recommendations set forth within and will provide training to appropriate staff responsible for monitoring expenses on the program. Refer to management’s corrective action plan for additional information.

Corrective Action Plan

Internal Controls over Compliance and Compliance with the Period of Performance Compliance Requirement     Contact: Chris Holmes   Title: Controller  Phone Number: 202-235-1938  Estimated Completion Date – done  Corrective Action  The results of the 2023 audit will be shared with appropriate staff and reiterated in training to ensure that adequate attention and guidance is provided on the allowability of trailing costs and the unallowability of newly incurred costs. During 2023, PSI resumed delivering in person training to its global finance and program staff and will continue to offer training during 2024.

Categories

Questioned Costs Subrecipient Monitoring Period of Performance

Other Findings in this Audit

  • 401766 2023-001
    Significant Deficiency Repeat
  • 401767 2023-002
    Significant Deficiency
  • 401768 2023-004
    Significant Deficiency Repeat
  • 401769 2023-003
    Significant Deficiency Repeat
  • 401770 2023-003
    Significant Deficiency Repeat
  • 401771 2023-002
    Significant Deficiency
  • 401772 2023-003
    Significant Deficiency Repeat
  • 401773 2023-001
    Significant Deficiency Repeat
  • 401774 2023-002
    Significant Deficiency
  • 401775 2023-004
    Significant Deficiency Repeat
  • 401777 2023-002
    Significant Deficiency
  • 401778 2023-004
    Significant Deficiency Repeat
  • 401779 2023-005
    Significant Deficiency Repeat
  • 401780 2023-002
    Significant Deficiency
  • 401781 2023-004
    Significant Deficiency Repeat
  • 401782 2023-004
    Significant Deficiency Repeat
  • 401783 2023-004
    Significant Deficiency Repeat
  • 401784 2023-003
    Significant Deficiency Repeat
  • 401785 2023-001
    Significant Deficiency Repeat
  • 401786 2023-001
    Significant Deficiency Repeat
  • 978208 2023-001
    Significant Deficiency Repeat
  • 978209 2023-002
    Significant Deficiency
  • 978210 2023-004
    Significant Deficiency Repeat
  • 978211 2023-003
    Significant Deficiency Repeat
  • 978212 2023-003
    Significant Deficiency Repeat
  • 978213 2023-002
    Significant Deficiency
  • 978214 2023-003
    Significant Deficiency Repeat
  • 978215 2023-001
    Significant Deficiency Repeat
  • 978216 2023-002
    Significant Deficiency
  • 978217 2023-004
    Significant Deficiency Repeat
  • 978218 2023-005
    Significant Deficiency Repeat
  • 978219 2023-002
    Significant Deficiency
  • 978220 2023-004
    Significant Deficiency Repeat
  • 978221 2023-005
    Significant Deficiency Repeat
  • 978222 2023-002
    Significant Deficiency
  • 978223 2023-004
    Significant Deficiency Repeat
  • 978224 2023-004
    Significant Deficiency Repeat
  • 978225 2023-004
    Significant Deficiency Repeat
  • 978226 2023-003
    Significant Deficiency Repeat
  • 978227 2023-001
    Significant Deficiency Repeat
  • 978228 2023-001
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
98.U00 Usaid Cost Reimbursable Contracts and Other Awards $8.63M
98.001 Usaid Foreign Assistance for Programs Overseas $6.30M
98.001 Covid 19 - Usaid Foreign Assistance for Programs Overseas $145,831
12.350 Department of Defense Hiv/aids Prevention Program $54,674
93.318 Covid 19 - Protecting and Improving Health Globally: Building and Strengthening Public Health Impact, Systems, Capacity and Security $-275
93.067 Global Aids $-6,695
98.U00 Covid 19 - Usaid Cost Reimbursable Contracts and Other Awards $-178,808